SCHEMBL20239306

SCHEMBL20239306

CN(C(=O)O)S(=O)(=O)Cc1ccc(Oc2cc(CN)nc(C3CC3)n2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.34
PDE4D Q08499 1/20 0.34
DGAT2 Q96PD7 1/20 0.32
LOXL2 Q9Y4K0 1/20 0.32
F10 P00742 1/20 0.32
PRSS1 P07477 1/20 0.32
PRSS2 P07478 1/20 0.32
PRSS3 P35030 1/20 0.32
ST14 Q9Y5Y6 1/20 0.32
NAPEPLD Q6IQ20 1/20 0.31
RORC P51449 1/20 0.31
PTPN1 P18031 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
MTNR1A P48039 1/20 0.31
MTNR1B P49286 1/20 0.31
MEN1 O00255 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20252443 0.88 GPR119 (0.32) PDE4BPDE4DDGAT2
SCHEMBL18249760 0.87 PDE4B (0.39) PDE4BPDE4DDGAT2NAPEPLDRORC
SCHEMBL16738673 0.85 LOXL2 (0.34) PDE4BDGAT2LOXL2PTPN1SMN1; SMN2
SCHEMBL20239258 0.85 PDE4B (0.34) PDE4BPDE4DNAPEPLDRORCSMN1; SMN2
SCHEMBL20239292 0.83 PTPN1 (0.33) PDE4BDGAT2LOXL2PTPN1SMN1; SMN2
SCHEMBL20239308 0.83 SMN1; SMN2 (0.34) PDE4BDGAT2LOXL2PTPN1SMN1; SMN2
SCHEMBL20239206 0.83 SMN1; SMN2 (0.37) PDE4BDGAT2LOXL2PTPN1SMN1; SMN2
SCHEMBL20239225 0.82 LOXL2 (0.37) PDE4BLOXL2MEN1KMT2ATRPM8
SCHEMBL20252430 0.76 SMN1; SMN2 (0.36) PDE4BPDE4DSMN1; SMN2MEN1KMT2A
SCHEMBL20252434 0.73 DPP4 (0.33) PDE4BPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT PDE4B 1093/4885PDE4D 2112/4885DGAT2 1/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT PDE4B 1262/4885PDE4D 2443/4885DGAT2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.